… that gefitinib and erlotinib appeared to have similar outcomes in patients with advanced/…
chemotherapy. The overall response rates and disease control rates in the gefitinib- and erlotinib…

… to be the sequela of previous platinum-based chemotherapy. … II trial of erlotinib or standard
chemotherapy in patients with … for patients who developed moderate to severe skin rash on …

… Therefore, we designed a study in patients who failed previous cytotoxic treatment to
compare PFS between erlotinib and intercalating erlotinib with pemetrexed for NSQ cell lung …

… (EGFR) pathway with tyrosine kinase inhibitor (TKI) is an effective and promising salvage
treatment for NSCLC patients who have failed previous chemotherapy, especially for Asian …

… EGFR status measured by immunohistochemistry was not a predictor of tumor response in
previous lung cancer clinical trials with erlotinib or gefitinib, a related EGFR tyrosine kinase …

… assigned 350 patients to receive erlotinib and 320 to receive placebo. We followed up patients
until … Exclusion criteria were previous treatment with any biological anticancer therapy; …

… combination of chemotherapy with erlotinib, followed by erlotinib maintenance therapy. …
administration of erlotinib with chemotherapy has demonstrated promising results in patients with …

… chemotherapy alone after the development of TKI resistance. We found that continuing
erlotinib with chemotherapy … a reasonable treatment option for patients with EGFR‐mutant lung …

… In this meta-analysis, continuous erlotinib plus chemotherapy versus chemotherapy alone
failed to show improvements in PFS and OS. A previous systematic review demonstrated that …

… The main exclusion criteria were previous exposure to anti-human-EGFR-directed drugs
or … and dihydrofolate reductase inhibitors); previous chemotherapy or systemic anti-neoplastic …